Early Changes in Incretin Secretion After Laparoscopic Duodenal–Jejunal Bypass Surgery in Type 2 Diabetic Patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A stomach-preserving duodenal–jejunal bypass (DJB) has been used for the treatment of type 2 diabetes mellitus (DM) since Rubino et al. first reported a prospective trial. However, there has been no report on changes in incretin secretion after DJB. We aimed to investigate whether DJB changes incretin secretion in nonmorbidly obese type 2 diabetic patients.
The inclusion criteria in this prospective study were: patient age of 20–65 years, body mass index of <30 kg/m2, a history of type 2 DM for ≤10 years, and fasting C-peptide ≥0.3 nmol/l. Six patients with type 2 DM without morbid obesity underwent DJB. Fasting plasma glucose and glycated hemoglobin (HbA1c) were measured. An oral glucose tolerance test (OGTT) was performed with measurement of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), insulin, C-peptide, and glucagon. The study subjects were followed up for 6 months.
The body weight of patients declined after surgery. The area under the curve (AUC) of glucose, peak glucose levels during OGTT, and HbA1c also declined until 3 months postoperatively. The AUC of C-peptide and insulin tended to increase postoperatively. The AUC of glucagon had a significant increase at 6 months postoperatively. The AUC of active GLP-1 increased at 1 month and at 6 months postoperatively. There was no change in the AUC of total GIP.
Our data suggest that DJB increases GLP-1 secretion in nonmorbidly obese type 2 diabetic patients. However, long-term data are needed to confirm this finding.
- King, H, Aubert, R, Herman, WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diab Care 21: pp. 1414-31 CrossRef
- Zimmet, P, Alberti, K, Shaw, J (2001) Global and societal implications of the diabetes epidemic. Nature 414: pp. 782-7 CrossRef
- Bloomgarden, ZT (2007) Diabetes and obesity: part 1. Diab Care 30: pp. 3145-51 CrossRef
- Rubino, F, Marescaux, J (2004) Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239: pp. 1-11 CrossRef
- Cohen, RV, Schiavon, CA, Pinheiro, JS (2007) Duodenal–jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 3: pp. 195-7 CrossRef
- Shafrir, E (1997) Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Diab Metab 22: pp. 131-48
- Detournay, B, Cross, S, Charbonnel, B (2000) Managing type 2 diabetes in France: the ECODIA survey. Diab Metab 26: pp. 363-9
- Scopinaro, N, Marinari, G, Camerini, GB (2005) Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diab Care 28: pp. 2406-11 CrossRef
- Tejirian, T, Jensen, C, Dutson, E (2008) Bariatric surgery and type 2 diabetes mellitus: surgically induced remission. J Diab Sci Technol 2: pp. 685-91
- Buchwald, H, Avidor, Y, Braunwald, E (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 13: pp. 1724-37 CrossRef
- Mingrone, G, Castagneto-Gissey, L (2009) Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diab Metab 35: pp. 518-23 CrossRef
- Rubino, F, Gagner, M (2002) Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236: pp. 554-9 CrossRef
- Patriti, A, Facchiano, E, Sanna, A (2004) The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 14: pp. 840-8 CrossRef
- Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56.e245.
- Gumbs, AA, Modin, I, Ballantyne, GH (2005) Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg 15: pp. 462-73 CrossRef
- Lin, E, Davis, S, Srinivasan, J (2009) Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass. Am Surg 75: pp. 498-502
- Rubino, F, Forgione, A, Cummings, D (2006) The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244: pp. 741-9 CrossRef
- Laferrère, B, Heshka, S, Wang, K (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care 30: pp. 1709-16 CrossRef
- Mingrone, G, DeGaetano, A, Greco, AV (1997) Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 40: pp. 599-605 CrossRef
- Noya, G, Cossu, M, Coppola, M (1998) Biliopancreatic diversion preserving the stomach and pylorus in the treatment of hypercholesterolemia and diabetes type II: results in the first 10 cases. Obes Surg 8: pp. 67-72 CrossRef
- Early Changes in Incretin Secretion After Laparoscopic Duodenal–Jejunal Bypass Surgery in Type 2 Diabetic Patients
Volume 20, Issue 11 , pp 1530-1535
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Duodenal–jejunal bypass
- Metabolic surgery
- Type 2 diabetes mellitus
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, The Catholic University of Korea, Seoul, Korea
- 2. Department of Internal Medicine, The Catholic University of Korea, Yeouido St. Mary’s Hospital, 62 Yeouido-dong, Youngdeungpo-gu, Seoul, 150-713, Korea